On April 26, 2011 at room K102, Faculty of Science, Mahidol University held a press conference,
“R & D in Pediatric Cancer Treatment and Innovation in Cancer Drug Delivery System” chaired by
Assoc. Prof. Suradej Hongeng, M.D., Department of Pediatrics, Faculty of Medicine Ramathibodi Hospital, Mahidol University, and
Dr. Norased Nasongkla, Ph.D., Department of Biomedical Engineering, Faculty of Engineering, Mahidol University.
“Pediatric cancer can be found in children ranging from 1-15 years of age. Approximately 1,000-1,500 cases are found annually. Early diagnosis generally yield upto 80% successful treatment rate with exception of brain cancer having 30-40% chance. Recently, new innovation in clinical treatment provides new hope for the future.” Assoc. Prof. Suradech says.
Dr. Norased, an innovator of biopolymers and nanoengineering for drug delivery, stated, “Brain cancer is difficult to reach due to the presence of blood-brain barrier, and clinical chemotherapy treatment depends on renal drug clearance through urine, which is a limitation of the treatment. Most drugs are removed from the body prior to exerting the therapeutic effect. Novel drug delivery methodology has been innovated to deliver the drug directly to the brain cancer. This novel innovation is called nanopolymer in drug delivery, which could exert its effect on cancer cells without affecting the neighboring organ.”
“Scientific and research community recently developed another novel brain cancer drug delivery system using wafers, which is a gel polymer that contain chemotherapeutic agent. The wafer is attached onto the cancer tissue, and the drug will absorb into the tissue. Absorption and distribution of the drug is not always effective, and the wafer may break down, leading to subsequent complications. This new innovation remains costly, up to one million Baht. Another innovation is direct drug injection into the middle of cancer tissue using another chemotherapeutic agent called SN-38 that will absorb outwardly at a controllable rate,” Dr. Norased said. “This method is currently in the pre-clinical trial phase, and the results are expected in this year. Clinical trial is expected to begin in 1-2 years.”
Date : April 28, 2011